A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

In a randomized trial, 48 weeks of treatment with bulevirtide, which inhibits hepatitis D virus entry into hepatocytes, reduced HDV RNA and alanine aminotransferase levels in patients with chronic hepatitis D.

Uložené v:
Podrobná bibliografia
Vydané v:The New England journal of medicine Ročník 389; číslo 1; s. 22 - 32
Hlavní autori: Wedemeyer, Heiner, Aleman, Soo, Brunetto, Maurizia Rossana, Blank, Antje, Andreone, Pietro, Bogomolov, Pavel, Chulanov, Vladimir, Mamonova, Nina, Geyvandova, Natalia, Morozov, Viacheslav, Sagalova, Olga, Stepanova, Tatyana, Berger, Annemarie, Manuilov, Dmitry, Suri, Vithika, An, Qi, Da, Ben, Flaherty, John, Osinusi, Anu, Liu, Yang, Merle, Uta, Schulze zur Wiesch, Julian, Zeuzem, Stefan, Ciesek, Sandra, Cornberg, Markus, Lampertico, Pietro
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Massachusetts Medical Society 06.07.2023
Predmet:
ISSN:0028-4793, 1533-4406, 1533-4406
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:In a randomized trial, 48 weeks of treatment with bulevirtide, which inhibits hepatitis D virus entry into hepatocytes, reduced HDV RNA and alanine aminotransferase levels in patients with chronic hepatitis D.
Bibliografia:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Undefined-1
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2213429